Background Atopic dermatitis (AD) affects children of all skin types. Most research has focused on light skin types. Studies investigating biomarkers in people with AD with dark skin types are lacking. Objectives To explore skin barrier and immune response biomarkers in stratum corneum (SC) tape strips from children with AD with different skin types. Methods Tape strips were collected from lesional and nonlesional forearm skin of 53 children with AD and 50 controls. We analysed 28 immunomodulatory mediators, and natural moisturizing factors (NMF) and corneocyte morphology. Results Interleukin (IL)-1b, IL-18, C-X-C motif chemokine (CXCL) 8 (CXCL8), C-C motif chemokine ligand (CCL) 22 (CCL22), CCL17, CXCL10 and CCL2 were significantly higher (P < 0Á05) in lesional AD skin compared with nonlesional AD skin; the opposite trend was seen for IL-1a. CXCL8, CCL2 and CCL17 showed an association with objective SCORing Atopic Dermatitis score. NMF levels showed a gradual decrease from healthy skin to nonlesional and lesional AD skin. This gradual decreasing pattern was observed in skin type II but not in skin type VI. Skin type VI showed higher NMF levels in both nonlesional and lesional AD skin than skin type II. Corneocyte morphology was significantly different in lesional AD skin compared with nonlesional AD and healthy skin. Conclusions Minimally invasive tape-stripping is suitable for the determination of many inflammatory mediators and skin barrier biomarkers in children with AD. This study shows differences between children with AD with skin type II and skin type VI in NMF levels, suggesting that some aspects of pathophysiological mechanisms may differ in AD children with light versus dark skin types.
Summary
Background Atopic dermatitis (AD) affects children of all skin types. Most research has focused on light skin types. Studies investigating biomarkers in people with AD with dark skin types are lacking. Objectives To explore skin barrier and immune response biomarkers in stratum corneum (SC) tape strips from children with AD with different skin types. Methods Tape strips were collected from lesional and nonlesional forearm skin of 53 children with AD and 50 controls. We analysed 28 immunomodulatory mediators, and natural moisturizing factors (NMF) and corneocyte morphology. Results Interleukin (IL)-1b, IL-18, C-X-C motif chemokine (CXCL) 8 (CXCL8), C-C motif chemokine ligand (CCL) 22 (CCL22), CCL17, CXCL10 and CCL2 were significantly higher (P < 0Á05) in lesional AD skin compared with nonlesional AD skin; the opposite trend was seen for IL-1a. CXCL8, CCL2 and CCL17 showed an association with objective SCORing Atopic Dermatitis score. NMF levels showed a gradual decrease from healthy skin to nonlesional and lesional AD skin. This gradual decreasing pattern was observed in skin type II but not in skin type VI. Skin type VI showed higher NMF levels in both nonlesional and lesional AD skin than skin type II. Corneocyte morphology was significantly different in lesional AD skin compared with nonlesional AD and healthy skin. Conclusions Minimally invasive tape-stripping is suitable for the determination of many inflammatory mediators and skin barrier biomarkers in children with AD. This study shows differences between children with AD with skin type II and skin type VI in NMF levels, suggesting that some aspects of pathophysiological mechanisms may differ in AD children with light versus dark skin types.
What's already known about this topic?
• Atopic dermatitis (AD) affects children of all skin types, but most research is focused on white people with light skin types.
• Studies investigating biomarkers in patients with AD with dark skin types are lacking.
• Tape-stripping can be used for analysis of skin barrier and immune response biomarkers in AD skin.
What does this study add?
• Stratum corneum tape-stripping is suitable to study a broad panel of biomarkers in children with AD.
• We show differences in skin barrier and immune response biomarkers between lesional, nonlesional and control skin.
• Immune response biomarkers are similar in light and dark skin types. However, natural moisturizing factor levels differ between skin types II and VI, suggesting a different pathogenesis in AD between light and dark skin types.
Atopic dermatitis (AD) is a chronic inflammatory skin disease affecting 10-20% of children.
1 AD affects children of all skin types and is more prevalent in Asian children and children with dark skin types. 2, 3 However, most research is focused on white people with light skin types, and studies investigating biomarkers in patients with AD with dark skin types are lacking. Data on physiological skin properties in different skin types is conflicting. Darker skin types seem more resistant to irritants than lighter skin types, 4 but transepidermal water loss (TEWL) is greater in dark skin types than in lighter skin types. 5 Furthermore, the stratum corneum (SC) of dark skin types has a higher lipid content and is more compact, owing to greater intercellular cohesion. 6, 7 Nevertheless, the SC thickness is demonstrated to be similar for all different skin types. 8 The SC and filaggrin (FLG) have a crucial role in forming the epidermal barrier. 9 FLG degradation products, such as histidine, pyrolidone-5-carboxylic acid and urocanic acid, are the main source of natural moisturizing factors (NMF) and are responsible for mechanical properties, skin hydration and inflammatory response in skin. 10 In patients with AD, abnormalities in corneocyte morphology such as prominent villus-like projections (VPs) have been observed using high-resolution atomic force microscopy (AFM). 11, 12 Although the nature of these VPs is not well understood, VPs can be used to measure skin barrier function. 11 The number of VPs per investigated corneocyte area is expressed as the Dermal Texture Index (DTI) score. In children with AD, a strong negative association was found between NMF levels and corneocyte morphology abnormalities measured by DTI. 13 Moreover, these DTI values in children with AD with FLG mutations might explain phenotypic differences in AD. 13 Serum inflammatory profiles are investigated to gain more insight in immune pathways and future personalized therapeutic options. Cytokines [interleukin (IL)-4, C-X-C motif chemokine (CXCL)8, IL-13] and chemokines [C-C motif chemokine ligand (CCL)2, CCL17, CCL18, CCL22] are correlated with AD severity in adults. [14] [15] [16] However, obtaining blood samples and skin biopsies is difficult in children; therefore, detailed data of skin samples are lacking. A minimally invasive method to detect biomarkers would provide an essential tool in dissection of childhood AD into disease endotypes, and predicting or monitoring flares and therapy efficacy in childhood AD.
Our aim was to use the minimally invasive method of SC tape-stripping to study a large array of SC biomarkers, including immunomodulatory mediators, NMF and DTI in children with AD compared with children with healthy skin (controls). We assessed differences in these biomarkers in light skin types vs. dark skin types, and in children with and without FLG mutations.
Patients and methods

Patients with atopic dermatitis and healthy controls
Children with atopic dermatitis and healthy controls (aged 0-12 years) diagnosed with AD according to the U.K. working party criteria were recruited (2015-16) from the paediatric and dermatology outpatient clinic in a tertiary referral centre, Amsterdam UMC (Amsterdam UMC University of Amsterdam, Amsterdam, the Netherlands). [17] [18] [19] Children treated with systemic corticosteroids, antibiotics, antimycotics or extensive ultraviolet (UV) exposure 4 weeks prior to tape-stripping were excluded, and children were instructed not to use antihistamines (for 72 h prior) and emollients, soap and perfumes on the selected forearm (for 48 h prior). For children with AD the forearm skin should not have been treated with topical corticosteroids (for 1 week prior). AD severity was assessed using the objective SCORing Atopic Dermatitis score (oSCORAD). 20, 21 Control children (no medical history of inflammatory skin disorders or AD, and no first-degree relatives with AD) with healthy skin were recruited from the Amsterdam UMC, University of Amsterdam surgery outpatient clinic.
Skin types were categorized according to Fitzpatrick skin phototypes, ranging from I to VI. 22 Analyses were limited to skin types II and VI owing to low sample sizes of remaining skin types.
Stratum corneum tape-stripping
The SC was collected, as previously described, 23 by tape-stripping a visibly nonlesional skin site of the forearm, and in some children with AD also from a lesional site of the forearm. Circular adhesive tapes (22 mm diameter, 3Á8 cm 2 , Dsquame â Discs; Monaderm, Monaco, France) were placed onto the volar forearm and pressed for 10 s with a pressure of 225 g cm À2 , using a D-Squame Pressure Instrument D500
(CuDerm Corporation, Dallas, TX, U.S.A.). Sequentially, six consecutive tapes from the same skin site were collected. The third and fourth tape strip for determining corneocyte morphology and NMF were stored at -20°C; all other tape strips were stored at -80°C until analysis.
Filaggrin genotyping
We analysed the four most prevalent FLG mutations (R501X, 2282del4, R2477X,S3247X) from DNA extracted from a buccal swab as previously described.
24,25
Immunomodulatory mediators Levels of 28 immunomodulatory mediators (IL-1a, IL-1b, IL-2, IL-4, IL-5, IL-6, IL-7, IL-10, IL-12p40, IL-12p70, IL-13, IL-15, IL-16, IL-17A, IL-18, interferon-c, tumour necrosis factor-a, granulocyte-macrophage colony-stimulating factor, CXCL8, CXCL10, CCL2, CCL3, CCL4, CCL11, CCL13, CCL17, CCL22 and CCL26) were determined in the fifth and sixth tape strip, representing the SC middle part, using the MESO QuickPlex SQ 120 assay (MSD, Rockville, MD, U.S.A.) on samples extracted by ultrasonification (15 min) with 0Á5 mL phosphate-buffered saline containing 0Á05% Tween 20 and stored at -80°C according to manufacturer's protocol. Samples under the limit of detection were substituted for by a value of half the level of the detection limit. Levels were corrected by total protein content, as determined using Pierce Micro BCA protein assay kit (Thermo Fisher Scientific, Rockford, IL, U.S.A.).
Natural moisturizing factor determination
The NMF components pyrolidone-5-carboxylic acid, histidine and urocanic acid (cis and trans isomer) were extracted with 500 lL 25% (w/w) ammonia solution, reconstituted in 500 lL water after evaporating ammonia and analysed by UV high-performance liquid chromatography as described previously. 23, 26 NMF concentrations were also corrected for total protein content and expressed as mmol g À1 protein.
Corneocyte morphology (Dermal Texture Index)
In a randomly chosen subgroup (16 controls and 21 children with AD) with skin type II or VI, corneocyte morphology was analysed with AFM, as described previously. 27, 28 Besides analysis of nonlesional skin, in 13 children with AD, DTI was also determined in lesional skin. AFM was used on the third tape strip with a Nanoscope III controller and software version 5.30sr3 (Digital Instruments, Santa Barbara, CA, U.S.A.). 27 For nanotexture analysis, subcellular scan areas of (20 lm) 2 were recorded. 13 A recently developed software method can quantitatively determine the VP surface nanotexture of corneocytes. Topographical data of cell surfaces of the tape strips were analysed using the Anostic method, applying custom-built, proprietary algorithms, 13 enabling assessment of the number of nanosize protrusion. Multiple linear regression analysis was performed with skin severity as the dependent variable, and biomarkers, skin type and FLG mutations as independent variables using the stepwise backward selection method. Because of skewed distribution, cytokine levels were log-transformed before linear regression analysis. Correction for multiple testing, using the Benjamini-Hochberg method was conducted for all the resulting P-values. Corrected P-values < 0Á05 were considered significant.
Ethical statement
The study was conducted according to principles of the Declaration of Helsinki and was approved by AMC's ethics committee; it was also approved by the Medical Ethics Review Committee of AMC Amsterdam (METC 2013_372). Written informed consent was obtained from both parents/legal guardians of all children.
Results
Patient characteristics
Demographic characteristics are shown in Table 1 . Control children were slightly older. AD severity was mild to moderate, with a mean AE SD oSCORAD of 17Á6 AE 9Á7. Within the AD group, FLG mutations were less prevalent in darker skin types, as only one child with skin type VI (n = 1/14; 7%) had an FLG mutation, whereas 64% (n = 9/14) of children with AD with skin type II had an FLG mutation. Most children were investigated in summer (76% controls vs. 49% children with AD).
Distinct inflammatory immune responses can be detected in the stratum corneum of children with atopic dermatitis From 28 measured immunomodulatory mediators 13 could quantitatively be determined in SC samples. In nine of the 13 immunomodulatory mediators significant differences were found between healthy, nonlesional and/or lesional skin. IL1a was significantly lower (P < 0Á05) in nonlesional AD skin compared with healthy skin of controls, which was even more pronounced (P < 0Á01) when compared with lesional AD skin (Fig. 1a) . A similar incremental pattern from healthy to nonlesional and lesional skin, but in the opposite direction, was seen for IL-1b and IL-18 (Fig. 1b,c) . CXCL8 and CCL2, CCL22 and CCL17 were significantly higher in lesional AD skin compared with healthy and nonlesional AD skin (Fig. 2a-c,e) . The opposite pattern was found for CCL4, which was significantly reduced in nonlesional and/ or lesional AD skin compared with healthy skin (Fig. 2d) . Significant differences between healthy and nonlesional skin, and between nonlesional and lesional skin were found for chemokine CXCL10 (Fig. 2f) . No significant differences in IL-4, IL-13, CCL13 or CCL11 levels were found between healthy skin, lesional and nonlesional AD skin (data not shown).
Although for a few cytokines the level of significance in comparisons between healthy, nonlesional and/or lesional skin differed between skin types II and VI, the overall pattern was similar for these two skin types ( Fig. S1 ; see Supporting Information).
Inflammatory immune responses correlate with severity of atopic dermatitis
Associations between oSCORAD and immunomodulatory mediators are shown in Table 2 . CXCL8 was significantly correlated with oSCORAD in both lesional and nonlesional AD skin. CCL17 showed a significant correlation with oSCORAD in nonlesional AD skin and a trend towards a significant correlation in lesional AD skin (P = 0Á053). In lesional AD skin, CCL2 was significantly correlated with oSCORAD. The relationship between oSCORAD and biomarkers was further investigated with multivariate linear regression analysis, including a set of biomarkers that were significantly correlated with oSCORAD in nonlesional and/or lesional AD skin (CXCL8, CCL2 and CCL17). Next to these three biomarkers, we included FLG mutations and skin types as independent variables. In nonlesional AD skin, the model with CXCL8, CCL2, CCL17, skin type and FLG mutation showed a significant effect on oSCORAD (r = 0Á50, P < 0Á05). In lesional AD skin, only CXCL8 and skin type were significant predictors of oSCORAD (r = 0Á52, P < 0Á05). In general, prediction of oSCORAD did not substantially improve compared with single biomarkers (Table 2) .
Natural moisturizing factor levels gradually decrease from healthy skin to nonlesional and lesional atopic dermatitis skin NMF levels gradually decreased from healthy skin [median 3Á1; interquartile range (IQR) 2Á0-4Á1] to nonlesional AD skin (median 2Á8; IQR 1Á8-3Á6), with a further decrease in lesional AD skin (median 1Á9 mmol g À1 protein; IQR 1Á0-3Á6), but no significant differences were found (Fig. 3a) . Although NMF levels in FLG mutation carriers were lower than in control participants, there was no significant difference between the groups (Fig. 3b) .
Natural moisturizing factor levels have different profiles in light and dark skin types
NMF levels were significantly lower in skin type II samples compared with skin type VI samples in both lesional and nonlesional AD skin (P < 0Á05; Fig. 4b, c) . In healthy skin, NMF levels were not different between skin types (Fig. 4a) . When comparing NMF between healthy, nonlesional and lesional skin within skin types, NMF levels in skin type II samples decreased sequentially in healthy skin to nonlesional and to lesional AD skin (Fig. 5a) , reaching significance when comparing healthy skin with lesional AD skin (P < 0Á01). No significant differences were seen when analysing only FLG wild-type participants, although a similar decreasing trend was seen (Fig. 5b) . In contrast, in skin type VI samples, NMF levels were not significantly different between healthy skin and either nonlesional or lesional AD skin (Fig. 5c ). Atopic dermatitis skin has altered corneocyte texture in both lesional and nonlesional skin Figure 6 shows representative AFM images of the surfaces of corneocytes sampled from lesional and nonlesional skin of children with AD and of healthy skin. DTI values were significantly higher in lesional AD skin compared with both nonlesional AD skin (P < 0Á05) and healthy skin (P < 0Á01; Fig. 7) . DTI values within skin type II showed a sequential increase from healthy skin to nonlesional and lesional AD skin, with a significant difference between healthy skin and lesional AD skin (Fig. 8a) . There was no significant difference between healthy, nonlesional and lesional AD skin in skin type VI (Fig. 8b) .
Discussion
The SC is largely responsible for skin barrier function. Furthermore, the SC harbours a large variety of inflammatory mediators involved in immune responses. Skin biomarkers research in children with AD is hampered by the invasiveness of sampling techniques, such as skin biopsy or blood collection. To the best of our knowledge, the present study shows, for the first time, that the minimally invasive method of SC tapestripping is suitable for determination of a large array of skin barrier and immune response biomarkers in children with AD, investigating differences between AD skin and healthy control skin. Furthermore, it is the first time that biomarker differences have been investigated in light and dark skin types. There were significant differences in several immunomodulatory mediators between healthy and atopic skin. IL-1a -an IL-1 cytokine constitutively produced by keratinocytes and present in the SC in large amounts -showed significant differences between healthy and nonlesional AD skin, and even more pronounced differences between healthy and lesional AD skin. As IL-1a is stored within the corneocyte, skin barrier damage leads to leakage of IL-1a into the extracellular space. A similar effect was seen in irritant contact dermatitis, which is associated with skin barrier damage. 29 IL-1b and IL-18 -two other IL-1 family cytokines -also showed significant differences between healthy and lesional AD skin and between nonlesional and lesional AD skin. IL-18 is associated with Staphylococcus aureus colonization, a common feature in AD. 30 A decrease of IL-1a and increase of IL-1b and IL-18 from healthy skin to nonlesional to lesional AD skin is in agreement with data from a previous study of interstitial fluid in AD, which revealed that SC reflects the same cytokine milieu as viable epidermis. 31 Previously, a meta-analysis of literature data found serum CCL17 to be the most promising single biomarker of AD severity. Our data showed that CCL17 in nonlesional AD skin was significantly correlated with oSCORAD, and showed a trend towards correlation in lesional AD skin. Next to CCL17, a significant correlation with oSCORAD was found for CXCL8 in both lesional and nonlesional AD skin and for CCL2 in lesional AD skin. Interestingly, levels of CCL17 and CXCL8 showed a correlation with disease severity in nonlesional skin, suggesting that SC samples also provide information on systemic immune response, which is in agreement with a recent study reporting that nonlesional markers generally showed higher and more significant correlations with SCORAD than lesional markers. 32 One of the aims of the present study was to explore possible differences in immune response and skin barrier between , respectively]. The differences in IL-1 cytokines between healthy and AD skin were tested by Mann-Whitney U-test. Wilcoxon signed rank test was used to test differences between the unaffected and affected AD skin. *P < 0Á05, **P < 0Á01, ***P < 0Á001, ****P < 0Á0001 (BenjaminiHochberg corrected). different skin types. As the sample size within the skin-type groups was small, we performed comparisons only between the largest subgroups: light skin type II and dark skin type VI. There was no clear difference in the levels of immunomodulatory mediator profiles between these two subgroups. However, children with AD with skin type II showed lower NMF levels in both nonlesional and lesional AD skin than in skin type VI, although both groups had comparable disease severity. As FLG mutations are the main determinant of NMF and they were more prevalent in skin type II, we also performed the comparison in only the children without FLG mutations. When excluding FLG mutation carriers, NMF levels in the skin type II group still showed a trend towards a difference between healthy skin, lesional and nonlesional AD skin, suggesting an effect of AD on NMF levels in the light skin type.
Interestingly, within skin type VI, there was no significant difference in NMF between healthy skin and either nonlesional or lesional AD skin. Consistent with our study where only one carrier of FLG mutations within skin type VI was detected, different studies have reported that the prevalence of FLG mutations in African people with AD is very low compared with white Europeans. 33, 34 Although rare population-specific mutations cannot be excluded, it is not likely that they would have largely influenced the results on NMF levels found in the present study. DTI, another skin barrier parameter, showed a sequential increase from healthy skin to nonlesional and lesional AD skin within skin type II, with a significant difference seen between healthy skin and lesional AD skin. However, this pattern of gradual increase was not present in skin type VI and no significant differences were seen. In general, ; (e) CCL17; and (f) CXCL10. The differences in chemokine levels between healthy and AD skin were tested by the Mann-Whitney U-test. Wilcoxon signed rank test was used to test differences between nonlesional and lesional AD skin. *P < 0Á05, **P < 0Á01, ***P < 0Á001, ****P < 0Á0001 (Benjamini-Hochberg corrected). Table 2 Overall association of immunomodulatory mediators with severity of atopic dermatitis (AD)
Immunomodulatory mediator
Nonlesional AD skin (n = 53) Lesional AD skin (n = 24)
Spearman's rho BH corrected P-value Spearman's rho BH corrected P-value
Correlation considered significant (bold) if Benjamini-Hochberg (BH) corrected P-values < 0Á05 (two-tailed). IL, interleukin; CXCL, C-X-C motif chemokine; Th2, T helper 2; CCL, C-C motif chemokine ligand. . Data are median with interquartile ranges. A Mann-Whitney U-test was used to investigate significant differences between healthy skin and unaffected AD skin, as the Wilcoxon matched-pairs signed rank test was used to investigate differences between the paired samples of unaffected skin vs. affected AD skin. data on differences in skin barrier between different skin types and ethnicities are scarce. Several studies reported differences in TEWL, lipid content, ceramides, intercellular cohesion and skin pH in African American children vs. white people and East Asians. As TEWL, intercellular cohesion and skin pH are known to be affected by NMF, 5, 7, 35 it would be interesting to investigate whether the higher NMF levels found in children with skin type VI in the present study are correlated with these important parameters of skin barrier function. Our study has several limitations. The sample size was relatively small and not powered on differences between skin types; accordingly, subgroup analyses in all skin types were not possible. There was a significant difference in sampling period, as the majority (76%) of healthy controls were seen during summer vs. 49% of children with AD. UV exposure may have influenced NMF levels and DTI values in the controls. 36 In conclusion, collecting SC samples with the minimally invasive tape-stripping method is suitable for determination of a large array of immunomodulatory mediators and skin barrier biomarkers in children with AD. CXCL8, CCL2 and CCL17 are the most promising biomarkers to assess disease severity. This study shows that immunomodulatory mediator profiles are A Mann-Whitney U-test was used to investigate significant difference between healthy skin and nonlesional AD skin, as the Wilcoxon matched-pairs signed rank test was used to investigate differences between the paired samples of nonlesional and lesional AD skin. **P < 0Á01 (Benjamini-Hochberg corrected). Dermal Texture Index (DTI) in the stratum corneum in healthy skin of control (CTRL) children (CTRL •, n = 16), in nonlesional (NL) atopic dermatitis (AD) skin (NL ■, n = 21) and in lesional (L) AD skin (L ▲, n = 13). Red symbols represent the children with filaggrin mutation(s). Data are median AE interquartile range. The difference between the healthy subgroup and AD subgroups was tested with the Mann-Whitney U-test. Wilcoxon signed rank test was used to investigate differences between the paired samples of nonlesional and lesional AD skin. *P < 0.05, ** P < 0.01 (Benjamini-Hochberg corrected). similar in light and dark skin types but that NMF levels and DTI values differ between children with AD with skin type II and skin type VI. This may suggest a different role for skin barrier dysfunction in the pathogenesis of AD between light and dark skin types.
